Positive clinical and molecular effects observed, with improvements demonstrated in key exploratory efficacy endpoints - percent change in EASI, EASI-50,...
BOSTON, Nov. 27, 2023 (GLOBE NEWSWIRE) -- binx health, a healthcare technology and diagnostics company focused on making routine testing...
—Data at week 48 demonstrated that treatment with pegozafermin led to sustained statistically significant improvements across liver fat and non-invasive...
Gracell is pioneering use of a CD19/BCMA dual-targeted CAR-T cell therapy in refractory systemic lupus erythematosus, aiming for deeper and...
SYDNEY, Australia, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Limited (ASX: RCE, FSE: R9Q), the Company developing a new...
Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Anavex...
TORONTO, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”) today announced that...
- PDUFA target action date is May 25, 2024 - - FDA does not currently plan to hold Advisory Committee...
ATLANTA, GA and HOUSTON, TX, Nov. 27, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- NewRegen (OTC: NREG) and PickleJar Holdings,...
BERWYN, Pa., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company addressing neurodegenerative...
Fireside chat scheduled for Wednesday, November 29, 2023, at 2:10 PM ETNEW YORK, Nov. 27, 2023 (GLOBE NEWSWIRE) -- TG...
MELBOURNE, Australia and SAN FRANCISCO, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the...
Sernova announces research collaboration with Professor Antonia Follenzi, expert in Hemophilia A at the University of Piemonte OrientaleLONDON, Ontario and...
ANN ARBOR, Mich., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company" or "Kraig Labs"), the...
NEW HAVEN, Conn., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class...
Media ReleaseCOPENHAGEN, Denmark; November 27, 2023 U.S. Food and Drug Administration (FDA) grants Breakthrough Therapy Designation (BTD) for epcoritamab-bysp for...
If approved, ~3,000 people with DEB in the European Union could receive VYJUVEK to treat the underlying cause of the disease for...
- Pivotal Phase 3 Study of Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer Initiated in September 2022 - - Phase 2...
FORT WORTH, Texas, Nov. 27, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing...
NMRA-266 is a highly selective positive allosteric modulator of the M4 muscarinic receptor, a clinically validated target for the treatment...